NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy

Recruiting

Phase 1

NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy

Sponsor:

Nanobiotix

Code:

NCT03589339

Conditions

Radiotherapy

Immunotherapy

Microsatellite Instability-High Solid Malignant Tumour

Metastasis from Malignant Tumor of Liver

Squamous Cell Carcinoma of Head and Neck

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

NBTXR3

SABR

Nivolumab

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Nanobiotix on 2025-01-14.